Hypertonic/hyperoncotic saline attenuates microcirculatory disturbances after traumatic brain injury.
BACKGROUND
Traumatic brain injury (TBI) induces an acute inflammatory response characterized by early recruitment of inflammatory cells (white blood cells). Rapid resuscitation of TBI with hypertonic saline/dextran (HS/DEX) yields promising results in clinical and experimental studies. The purpose of this paper was to test the hypothesis that HS/DEX exerts its effects in part through a modulation of the acute inflammatory response to TBI.


METHODS
Rabbits equipped with chronic cranial windows underwent fluid-percussion injury and were followed up for 6 hours. Intravital fluorescence videomicroscopy technique was used to visualize white blood cell trafficking and to measure pia vessel diameters and venular shear rates. Three groups were studied: sham (group I, n = 5), trauma (group II, n = 7), and trauma and 4 mL/kg 7.2% NaCl/10% dextran 60 IV over 5 minutes at 10 minutes after TBI (group III, n = 7).


RESULTS
TBI in groups II and III led to significant increases of intracranial pressure. Arteriolar diameters after trauma increased by 17 +/- 8% at 6 hours in group II. Infusion of HS/DEX completely prevented this secondary diameters increase. At 6 hours, the increase of "sticking" white blood cells in group III was reduced by approximately 90% compared with group II.


CONCLUSIONS
Whether the anti-inflammatory effect of HS/DEX plays a role in reducing delayed brain damage (> 6 hours after TBI) or other systemic complications of TBI arises as an important question and should be investigated further.
Härtl
R
R
Aitken Neuroscience Institute, New York, NY 10021, USA.
Medary
M B
MB
Ruge
M
M
Arfors
K E
KE
Ghahremani
F
F
Ghajar
J
J
D000208:Acute Disease; D000818:Animals; D001930:Brain Injuries / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002675:Child, Preschool; D003911:Dextrans / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007249:Inflammation; D007962:Leukocytes / Q000276:immunology; D008833:Microcirculation / Q000187:drug effects*; D010952:Plasma Substitutes / Q000627:therapeutic use*; D011817:Rabbits; D012462:Saline Solution, Hypertonic / Q000627:therapeutic use*; D013997:Time Factors
D003911:Dextrans; D004338:Drug Combinations; D010952:Plasma Substitutes; D012462:Saline Solution, Hypertonic